103 related articles for article (PubMed ID: 35174936)
21. Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related.
Bos R; van Diest PJ; van der Groep P; Shvarts A; Greijer AE; van der Wall E
Breast Cancer Res; 2004; 6(4):R450-9. PubMed ID: 15217513
[TBL] [Abstract][Full Text] [Related]
22. Efp promotes in vitro and in vivo growth of endometrial cancer cells along with the activation of nuclear factor-κB signaling.
Sato W; Ikeda K; Urano T; Abe Y; Nakasato N; Horie-Inoue K; Takeda S; Inoue S
PLoS One; 2018; 13(12):e0208351. PubMed ID: 30586414
[TBL] [Abstract][Full Text] [Related]
23. The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.
Tanaka S; Suzuki K; Sakaguchi M
Breast Cancer; 2017 Sep; 24(5):658-666. PubMed ID: 28070831
[TBL] [Abstract][Full Text] [Related]
24. cGMP-dependent protein kinase I interacts with TRIM39R, a novel Rpp21 domain-containing TRIM protein.
Roberts JD; Chiche JD; Kolpa EM; Bloch DB; Bloch KD
Am J Physiol Lung Cell Mol Physiol; 2007 Oct; 293(4):L903-12. PubMed ID: 17601797
[TBL] [Abstract][Full Text] [Related]
25. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.
Esteban JM; Felder B; Ahn C; Simpson JF; Battifora H; Shively JE
Cancer; 1994 Sep; 74(5):1575-83. PubMed ID: 7914825
[TBL] [Abstract][Full Text] [Related]
26. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
27. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis.
Pinto AE; André S; Pereira T; Nóbrega S; Soares J
Ann Oncol; 2001 Apr; 12(4):525-33. PubMed ID: 11398888
[TBL] [Abstract][Full Text] [Related]
28. Roquin1 inhibits the proliferation of breast cancer cells by inducing G1/S cell cycle arrest via selectively destabilizing the mRNAs of cell cycle-promoting genes.
Lu W; Zhou M; Wang B; Liu X; Li B
J Exp Clin Cancer Res; 2020 Nov; 39(1):255. PubMed ID: 33228782
[TBL] [Abstract][Full Text] [Related]
29. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.
Ding J; Kuo ML; Su L; Xue L; Luh F; Zhang H; Wang J; Lin TG; Zhang K; Chu P; Zheng S; Liu X; Yen Y
Carcinogenesis; 2017 May; 38(5):519-531. PubMed ID: 28379297
[TBL] [Abstract][Full Text] [Related]
30. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
Lott ST; Chen N; Chandler DS; Yang Q; Wang L; Rodriguez M; Xie H; Balasenthil S; Buchholz TA; Sahin AA; Chaung K; Zhang B; Olufemi SE; Chen J; Adams H; Band V; El-Naggar AK; Frazier ML; Keyomarsi K; Hunt KK; Sen S; Haffty B; Hewitt SM; Krahe R; Killary AM
PLoS Med; 2009 May; 6(5):e1000068. PubMed ID: 19536326
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer.
Kurozumi S; Yamaguchi Y; Hayashi S; Hiyoshi H; Suda T; Gohno T; Matsumoto H; Takei H; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
Cancer Med; 2016 Aug; 5(8):1873-82. PubMed ID: 27334118
[TBL] [Abstract][Full Text] [Related]
32. A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer.
Burger AM; Gao Y; Amemiya Y; Kahn HJ; Kitching R; Yang Y; Sun P; Narod SA; Hanna WM; Seth AK
Cancer Res; 2005 Nov; 65(22):10401-12. PubMed ID: 16288031
[TBL] [Abstract][Full Text] [Related]
33. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
34. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
[TBL] [Abstract][Full Text] [Related]
35. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.
Bartlett JM; Thomas J; Ross DT; Seitz RS; Ring BZ; Beck RA; Pedersen HC; Munro A; Kunkler IH; Campbell FM; Jack W; Kerr GR; Johnstone L; Cameron DA; Chetty U
Breast Cancer Res; 2010; 12(4):R47. PubMed ID: 20615243
[TBL] [Abstract][Full Text] [Related]
36. Antineoplastic effects of α-santalol on estrogen receptor-positive and estrogen receptor-negative breast cancer cells through cell cycle arrest at G2/M phase and induction of apoptosis.
Santha S; Bommareddy A; Rule B; Guillermo R; Kaushik RS; Young A; Dwivedi C
PLoS One; 2013; 8(2):e56982. PubMed ID: 23451128
[TBL] [Abstract][Full Text] [Related]
37. FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression.
Lv Q; Guan S; Zhu M; Huang H; Wu J; Dai X
Technol Cancer Res Treat; 2021; 20():15330338211004935. PubMed ID: 33783288
[TBL] [Abstract][Full Text] [Related]
38. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
Lazennec G; Katzenellenbogen BS
Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
[TBL] [Abstract][Full Text] [Related]
39. ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.
Magnusson K; Gremel G; Rydén L; Pontén V; Uhlén M; Dimberg A; Jirström K; Pontén F
BMC Cancer; 2016 Nov; 16(1):904. PubMed ID: 27863473
[TBL] [Abstract][Full Text] [Related]
40. TRIM47 activates NF-κB signaling via PKC-ε/PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer.
Azuma K; Ikeda K; Suzuki T; Aogi K; Horie-Inoue K; Inoue S
Proc Natl Acad Sci U S A; 2021 Aug; 118(35):. PubMed ID: 34433666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
